

HCV Directly Acting Antivirals & RBV

Charts revised November 2020. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

Table of drug interactions for DCV, ELB/GZR, G/P, LED, OBV/PTV/r, OBV/PTV/r+DSV, SMV, SOF, SOF/VEL, SOF/VEL/VOX, and RBV. Categories include Anaesthetics & Muscle Relaxants, Analgesics, Anthelmintics, Antiarrhythmics, and Antibacterials.

Table of drug interactions for DCV, ELB/GZR, G/P, LED, OBV/PTV/r, OBV/PTV/r+DSV, SMV, SOF, SOF/VEL, SOF/VEL/VOX, and RBV. Categories include Antibacterials (continued), Anticoagulant, Antiplatelet & Fibrinolytic, and Anticonvulsants.

For personal use only. Not for distribution.

Key to symbols

Legend for symbols: red diamond (no coadministration), orange square (potential clinically significant interaction), yellow triangle (potential interaction likely to be of weak intensity), green diamond (no clinically significant interaction expected).

Notes

- Further information is available at www.hep-druginteractions.org
Predicted interactions are based on known metabolic pathways and routes of clearance.
Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF. We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Charts revised November 2020. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	SMV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Herbals/Supplements/Vitamins											
Aloe vera	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ascorbic acid (Vitamin C)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Black cohosh	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cat's claw (U. tomentosa)	■	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colecalciferol (Vitamin D3)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyanocobalamin (B12)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diosmin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Echinacea	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eucalyptus globulus	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Folic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Garlic	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginger (Z. officinale)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginkgo biloba	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginseng	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Goldenseal (H. canadensis)	■	■	■	◆	■	■	◆	◆	◆	◆	◆
Grape seed extract	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Grapefruit juice	■	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Green tea (C. sinensis)	▲	▲	▲	◆	▲	▲	▲	◆	◆	◆	◆
Homeopathic remedies	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Inula racemosa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iodine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iron supplements	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Kava kava	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Milk thistle	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Retinol (Vitamin A)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Riboflavin (Vitamin B2)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Serenoa repens	■	◆	◆	◆	■	■	◆	◆	◆	◆	◆
St John's wort	●	●	●	●	●	●	●	●	●	●	◆
Thiamine (Vitamin B1)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Turmeric (curcumin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valerian	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin E	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	SMV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
HIV Drugs											
<i>Entry/Integrase Inhibitors</i>											
Bictegravir/FTC/TAF	◆	◆	▲	◆	■	■	◆	◆	◆	◆	■
Dolutegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/rilpivirine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Elvitegravir/cobi /FTC/TAF	■	●	◆	◆	●	●	◆	◆	◆	◆	■
Elvitegravir/cobi/FTC/TDF	■	●	◆	◆	●	●	◆	◆	◆	◆	■
Ibalizumab-uiyk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Maraviroc	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Raltegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
<i>NNRTIs</i>											
Doravirine	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Doravirine/3TC/TDF	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	■
Efavirenz	■	●	●	■	●	●	◆	◆	◆	◆	◆
Etravirine	■	●	●	◆	●	●	◆	◆	◆	◆	◆
Nevirapine	■	●	●	◆	●	●	◆	◆	◆	◆	◆
Rilpivirine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Rilpivirine/dolutegravir	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Rilpivirine/FTC/TAF	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
<i>NRTIs</i>											
Abacavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Didanosine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●
Emtricitabine (FTC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Emtricitabine + TAF	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Emtricitabine + TDF	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Stavudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●
Tenofovir-DP (TDF)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Zidovudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●
<i>Protease Inhibitors</i>											
Atazanavir alone	◆	●	●	◆	■	■	◆	◆	◆	◆	■
Atazanavir/cobicistat	■	●	●	◆	●	●	◆	◆	◆	◆	■
Atazanavir + ritonavir	■	●	●	◆	●	●	◆	◆	◆	◆	■
Darunavir/cobicistat	◆	●	●	◆	●	●	◆	◆	◆	◆	◆
Darunavir/cobi/FTC/TAF	◆	●	●	◆	●	●	◆	◆	◆	◆	◆
Darunavir + ritonavir	◆	●	●	◆	■	■	◆	◆	◆	◆	■
Fosamprenavir	■	●	●	◆	■	■	◆	◆	◆	◆	◆
Indinavir	■	●	●	◆	●	●	◆	◆	◆	◆	◆
Lopinavir	◆	●	●	■	●	●	◆	◆	◆	◆	◆
Ritonavir	■	●	●	◆	●	●	◆	◆	◆	◆	■
Saquinavir	■	●	●	◆	●	●	◆	◆	◆	◆	◆
Tipranavir	■	●	●	●	●	●	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, Pharmacology Research Labs,
 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

Table with columns for drug classes (DCV, ELB/GZR, G/P, LED/SOF, OBV/PTV/r, OBV/PTV/r+DSV, SMV, SOF, SOF/VEL, SOF/VEL/VOX, RBV) and rows for various drugs including Acamprostate, Acetazolamide, Acitretin, etc.

Table with columns for drug classes (DCV, ELB/GZR, G/P, LED/SOF, OBV/PTV/r, OBV/PTV/r+DSV, SMV, SOF, SOF/VEL, SOF/VEL/VOX, RBV) and rows for drug classes including Oxytocics, Parkinsonism Agents, PBC Agents, Steroids, and Urological Agents.

For personal use only. Not for distribution.

Key to symbols

Table defining symbols: red circle for 'These drugs should not be coadministered', orange square for 'Potential clinically significant interaction...', yellow triangle for 'Potential interaction likely to be of weak intensity...', and green diamond for 'No clinically significant interaction expected'.

Notes

- Further information is available at www.hep-druginteractions.org
Predicted interactions are based on known metabolic pathways and routes of clearance.
Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF. We aim to ensure that information is accurate and consistent with current knowledge and practice.